<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26041765</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>04</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1569-8041</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>7</Issue>
<PubDate>
<Year>2015</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>
<ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists.</ArticleTitle>
<Pagination>
<MedlinePgn>1440-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdv028</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with hematologic malignancies often receive aggressive care at the end-of-life. To better understand the end-of-life decision-making process among oncology specialists, we compared the cancer treatment recommendations, and attitudes and beliefs toward palliative care between hematologic and solid tumor specialists.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We randomly surveyed 120 hematologic and 120 solid tumor oncology specialists at our institution. Respondents completed a survey examining various aspects of end-of-life care, including palliative systemic therapy using standardized case vignettes and palliative care proficiency.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 240 clinicians, 182 (76%) clinicians responded. Compared with solid tumor specialists, hematologic specialists were more likely to favor prescribing systemic therapy with moderate toxicity and no survival benefit for patients with Eastern Cooperative Oncology Group (ECOG) performance status 4 and an expected survival of 1 month (median preference 4 versus 1, in which 1 = strong against treatment and 7 = strongly recommend treatment, P &lt; 0.0001). This decision was highly polarized. Hematologic specialists felt less comfortable discussing death and dying (72% versus 88%, P = 0.007) and hospice referrals (81% versus 93%, P = 0.02), and were more likely to feel a sense of failure with disease progression (46% versus 31%, P = 0.04). On multivariate analysis, hematologic specialty [odds ratio (OR) 2.77, P = 0.002] and comfort level with prescribing treatment to ECOG 4 patients (OR 3.79, P = 0.02) were associated with the decision to treat in the last month of life.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found significant differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor specialists, and identified opportunities to standardize end-of-life care.</AbstractText>
<CopyrightInformation>Â© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Hui</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Departments of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA dhui@mdanderson.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bansal</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Departments of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Reddy</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Departments of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cortes</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fossella</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bruera</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Departments of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Ann Oncol</MedlineTA>
<NlmUniqueID>9007735</NlmUniqueID>
<ISSNLinking>0923-7534</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D001291">Attitude of Health Personnel</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019337">Hematologic Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008495">Medical Oncology</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009369">Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010465">Perception</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010818">Practice Patterns, Physicians'</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D013038">Specialization</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D013727">Terminal Care</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">chemotherapy</Keyword>
<Keyword MajorTopicYN="N">decision making</Keyword>
<Keyword MajorTopicYN="N">end-of-life care</Keyword>
<Keyword MajorTopicYN="N">hematologic neoplasms</Keyword>
<Keyword MajorTopicYN="N">palliative care</Keyword>
<Keyword MajorTopicYN="N">quality of healthcare</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>12</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>12</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26041765</ArticleId>
<ArticleId IdType="pii">mdv028</ArticleId>
<ArticleId IdType="doi">10.1093/annonc/mdv028</ArticleId>
<ArticleId IdType="pmc">PMC4855240</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Cancer. 2014 May 15;120(10):1572-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24549743</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Palliat Care. 2002 Spring;18(1):39-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12001402</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ Support Palliat Care. 2017 Mar;7(1):39-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25252939</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Apr 20;29(12):1587-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21402603</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Palliat Med. 2008 Apr;11(3):422-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18363482</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2010 Mar 17;303(11):1054-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20233823</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Hosp Palliat Care. 2002 Mar-Apr;19(2):103-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11926440</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pain Symptom Manage. 2013 Jul;46(1):1-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23211648</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA Intern Med. 2013 Feb 25;173(4):283-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23358690</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Palliat Med. 2010 Aug;13(8):1021-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20712465</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2010 Apr 15;116(8):2036-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20162701</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2009 Sep 20;27(27):4613-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19704067</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2014 Oct 1;32(28):3184-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25154824</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncologist. 2012;17(12):1574-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23220843</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Oncol Pract. 2014 Nov;10(6):e396-403</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25294393</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2004 Jan 15;22(2):315-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14722041</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Palliat Med. 2011 Sep;25(6):630-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21228094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Adv Nurs. 2012 Oct;68(10):2175-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22150339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Palliat Med. 2008 Jul;11(6):893-906</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18715182</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Palliat Med. 2014 Feb;17(2):195-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24383458</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leuk Res. 2013 Jul;37(7):731-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23490030</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2002 Sep 1;20(17):3658-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12202667</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>